Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live attenuated influenza vaccine monovalent
- Development stage
- Unknown
- Lead developer
- MedImmune
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Live attenuated influenza vaccine monovalent refers to single-strain formulations of live attenuated influenza vaccines (LAIV) developed for specific pandemic response or research purposes. These vaccines utilize cold-adapted, temperature-sensitive, and attenuated influenza virus strains that are administered intranasally. The attenuated virus replicates in the cooler environment of the nasopharynx, inducing a multifaceted immune response including mucosal IgA, systemic antibodies, and cellular immunity without causing systemic disease. During the 2009 H1N1 pandemic, monovalent LAIVs were developed by companies such as MedImmune (AstraZeneca) and the Serum Institute of India to target the A/California/7/2009 (H1N1)pdm09 strain. These vaccines are critical tools for pandemic preparedness, allowing for rapid response to emerging influenza threats.
- Brand names
- Nasovac
- Other names
- monovalent LAIVH1N1pdm09 LAIVH-1N1pdm09 LAIVH 1N1pdm09 LAIVmonovalent live attenuated influenza vaccine
02
Targets
SA (Sialic acid)
Beyond the preview
Go deeper on live attenuated influenza vaccine monovalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live attenuated influenza vaccine monovalent.